(redirected from Humanized antibodies)
Also found in: Dictionary, Thesaurus, Legal, Wikipedia.
Related to Humanized antibodies: Chimeric Antibody


tr.v. human·ized, human·izing, human·izes
a. To modify (a nonhuman compound, cell, organ, or organism) such that some of its components are replaced with human forms of those components, usually by means of genetic engineering.
b. To replace most of the variable region of (a monoclonal antibody from a nonhuman source) with a human sequence of amino acids so that the resulting antibody is more compatible with the human immune system.

hu′man·i·za′tion (-mə-nĭ-zā′shən) n.
hu′man·iz′er n.


Chemically altered to resemble natural human amino acid sequences. It applies to proteins or polypeptides derived from animals, e.g., mice, that are altered to reduce their antigenic potential.
References in periodicals archive ?
Protein Design has granted licenses and other rights under its antibody humanization patents to pharmaceutical and biotechnology companies worldwide covering more than 50 humanized antibodies, more than half of which are currently in clinical development.
PDL holds various important antibody-related patents, and has entered into agreements with numerous pharmaceutical and biotechnology companies for rights covering more than 40 humanized antibodies, more than half of which are in clinical development.
Merck is the twenty-eighth company to have signed an agreement with Protein Design related to humanized antibodies and our antibody humanization patents," said Robert L.
The company acquired early funding from the United States Army in June of 2004 to explore the development of new production technologies for humanized antibodies.
Therefore, humanized antibodies reduce or eliminate the HAMA response during treatment, making multiple treatments possible.
Protein Design has a strong intellectual property position in the antibody field, with issued patents in the United States, Europe and Japan that we believe cover most humanized antibodies," said Robert L.
The body's immune system can recognize the mouse protein found in chimeric and humanized antibodies as foreign and may launch an immune response.
PDL's proven technology and our ability to engineer effective humanized antibodies remain core strengths that can effectively attract new partners, such as Abbott.
PDL currently has three humanized antibodies in various stages of clinical testing for the treatment of inflammatory bowel disease.
The body's immune system can recognize the mouse protein found in chimeric and humanized antibodies as foreign and launch an immune response in the form of infusion reactions, allergic reactions or anaphylaxis.
With nearly 30 successful collaborative R&D programs with the biopharmaceutical industry, which have enabled at least seven humanized antibodies to enter clinical trials, AERES has established a world-wide reputation for its expertise in antibody humanization.